A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
Mar 1, 2022
0
39
Approximately 700 people are diagnosed with diffuse large B-cell lymphoma (DLBCL) in Finland each year. It is the most common cancer that originates from lymphocytes, immune system cells. Although the disease is treated with ...
Feb 21, 2022
0
7
Melanoma, a type of skin cancer, is often curable when detected and treated in its early stages. However, the disease can rapidly spread to other organs in the body and become deadly. According to the American Cancer Society, ...
Feb 17, 2022
0
20
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at ...
Feb 14, 2022
0
6
Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients' survival and was able to work within the brain, according to a study published in Clinical ...
Feb 10, 2022
0
5
A new study provides additional evidence of the efficacy of virotherapy for glioblastoma, the most deadly type of brain tumor. The research findings, published Feb. 1, 2022, in Clinical Cancer Research, indicate that an oncolytic ...
Feb 2, 2022
0
19
Glioblastoma, an aggressive cancer in the brain or spinal cord, has proven stubbornly resistant to newer immunotherapies. And radiation and chemotherapy, the standard treatment for glioblastoma, result in fewer than 10 percent ...
Jan 19, 2022
0
133
Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a ...
Jan 19, 2022
0
5
For patients with acute lymphoblastic leukemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly ...
Jan 12, 2022
0
8
A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms.
Jan 5, 2022
0
1805
